obesity | pharmaphorum

Monday 6 July 2026

obesity

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

R&D

Endoscopy

Sponsored

Obesity and the endoscopy space: Innovative, minimally invas...

According to the World Health Organization (WHO), in 2022, 2.5 billion adults aged 18 years and older were overweight, including over 890 million adults who were living with

News

Trump blocks plan for Medicare to cover weight-loss drugs

Trump blocks plan for Medicare to cover weight-loss drugs

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

News

Novo Nordisk looks east for another obesity therapy

Novo Nordisk looks east for another obesity therapy

Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk's CagriSema data disappoints investors again

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.